Alkermes Inc. plc (ALKS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Alkermes Inc. plc (ALKS)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key Insights
Critical company metrics and information
Share Price
$30.69Market Cap
$4.97 BillionTotal Outstanding Shares
161.80 Million SharesTotal Employees
2,100Dividend
No dividendIPO Date
July 16, 1991SIC Description
Pharmaceutical PreparationsHomepage
https://www.alkermes.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-488.97 Million |
| Net Cash Flow From Operating Activities | $355.96 Million |
| Net Cash Flow From Investing Activities | $-118.42 Million |
| Net Cash Flow, Continuing | $-251.42 Million |
| Net Cash Flow From Financing Activities, Continuing | $-488.97 Million |
| Net Cash Flow From Investing Activities, Continuing | $-118.42 Million |
| Net Cash Flow From Operating Activities, Continuing | $355.96 Million |
| Net Cash Flow | $-251.42 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $939.20 Million |
| Other Operating Expenses | $10.08 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Costs And Expenses | $1.19 Billion |
| Income Tax Expense/Benefit | $-54.78 Million |
| Gross Profit | $1.25 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Nonoperating Income/Loss | $19.60 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $332.18 Million |
| Basic Average Shares | $331.75 Million |
| Diluted Earnings Per Share | $1.98 |
| Benefits Costs and Expenses | $1.17 Billion |
| Income Tax Expense/Benefit, Deferred | $-20.20 Million |
| Research and Development | $261.08 Million |
| Net Income/Loss | $333.35 Million |
| Operating Income/Loss | $312.58 Million |
| Basic Earnings Per Share | $2.01 |
| Income/Loss From Continuing Operations After Tax | $386.95 Million |
| Income/Loss From Discontinued Operations Net Of Tax | $-53.61 Million |
| Revenues | $1.51 Billion |
| Cost Of Revenue | $253.34 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $333.35 Million |
| Net Income/Loss Attributable To Parent | $333.35 Million |
| Selling, General, and Administrative Expenses | $668.03 Million |
| Diluted Average Shares | $337.73 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $365.69 Million |
| Noncurrent Liabilities | $409.48 Million |
| Other Current Liabilities | $360.76 Million |
| Accounts Payable | $37.04 Million |
| Wages | $55.90 Million |
| Equity | $1.29 Billion |
| Noncurrent Assets | $591.11 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities | $863.18 Million |
| Accounts Receivable | $367.21 Million |
| Inventory | $191.09 Million |
| Assets | $2.16 Billion |
| Current Liabilities | $453.70 Million |
| Other Current Assets | $1.01 Billion |
| Current Assets | $1.56 Billion |
| Equity Attributable To Parent | $1.29 Billion |
| Fixed Assets | $225.42 Million |
| Liabilities And Equity | $2.16 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Alkermes Inc. plc (ALKS)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.